GLK-101-04

Glaucoma (ENROLLING)

ABOUT STUDY

• The objective of this study is to evaluate the safety and efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with uncomplicated cataract surgery compared to uncomplicated cataract surgery alone, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Study Details

Which eye

OD -or-  OS

How long is the study

12 Months

How many visits?

11

Co-management

No

GOOD CANDIDATE

• Generally healthy eyes
• Male or female, 45 years of age or older
• Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye.
• OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)
• If on IOP-lowering medication(s) at the screening visit, must be able to safely undergo washout from IOP-lowering medication in the study eye.
• Best spectacle corrected visual acuity of 20/80 or better in the fellow eye.

LEAD COORDINATOR

• mckenzie.schueller@vancethompsonvision.com

CROMA: CPH-50601

Cataract/Lens/VISCO (ENROLLING)

ABOUT STUDY

• The purpose of this study is to demonstrate the safety and efficacy of NuVisc PRO, a new OVD that is already commercially available in Europe. The primary effectiveness endpoint is preservation of endothelial cells.
•  Subjects randomized to the AMVISC or test Visco

• Randomization ratio: 1:1

• Patients are masked throughout study

Study Details

Which eye

OD -or-  OS

How long is the study

5-6 months

How many visits?

6

Co-management

No

GOOD CANDIDATE

• Generally healthy eyes
• BCVA >20/80
• Endothelial cell density >1500 cells/mm^2
• IIOP < 21mmHg

LEAD COORDINATOR

• Hannah.Christensen@vancethompsonvision.com